Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study
Meng Zhang,
Mei Liu,
Xiao Wang,
Peng Wang,
Hua Ye,
Qi Yu,
Jianying Zhang,
Yaoguang Li,
Zihao Fan,
Dongqi Shen,
Xueying Huang,
Feng Ren,
Liping Dai,
Jianxiang Shi,
Xiaoang Yang,
Shunxiang Zhang
Affiliations
Meng Zhang
Department of Neurology, Daping Hospital & Research Institute of Surgery, The Army Military Medical University, Chongqing, China
Mei Liu
Department of Oncology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Xiao Wang
Henan Academy of Medical and Pharmaceutical Sciences & BGI College, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Peng Wang
State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Hua Ye
1 Department of Rheumatology and Immunology, Peking University People`s Hospital, Beijing, China
Qi Yu
The First Affiliated Hospital Of Zhengzhou University, Zhengzhou, China
Jianying Zhang
Department of Epidemiology and Health Statistics & Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Yaoguang Li
Department of Epidemiology and Health Statistics & Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Zihao Fan
Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Dongqi Shen
Hepatobiliary and Pancreatic Surgery, The First Affillated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
Xueying Huang
Department of Oncology, Beijing Youan Hospital, Capital Medical University, Beijing, People’s Republic of China
Feng Ren
1Insilico Medicine, Shanghai, China
Liping Dai
State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Jianxiang Shi
State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Xiaoang Yang
Henan Academy of Medical and Pharmaceutical Sciences & BGI College, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Shunxiang Zhang
Department of Epidemiology and Health Statistics & Henan Key Laboratory for Tumor Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
Objectives The health-related quality of life (HRQoL) and utilities of patients with chronic hepatitis B (CHB) virus infection, including compensated cirrhosis (CC), decompensated cirrhosis (DC) and different stages of hepatocellular carcinoma (HCC), have not been well described in China. This study aimed to evaluate HRQoL and utilities and provide parameters for the economic evaluation of CHB-related diseases.Methods We conducted a multicentre cross-sectional and study to measure the HRQoL of patients with CHB, CC, DC and HCC using the Chinese short form (SF) 36 health survey V.2. The utilities were extracted based on the SF-six dimension scoring model. Multivariable regression analyses identified the effects on HRQoL.Results A total of 1071 patients (639 with CHB, 125 with CC, 85 with DC and 222 with HCC) were invited to complete the questionnaire. Physical HRQoL was not impaired in the CHB stage, while mental HRQoL was significantly impaired. Physical composite summary scores have a more significant decrease than mental composite summary scores at the advanced stages (CC, DC and HCC). The utility scores of CHB only, CC, DC and HCC were 0.773, 0.750, 0.683 and 0.640, respectively. The utility scores in the early, middle and terminal stages of HCC were 0.656, 0.635 and 0.615, respectively.Conclusion Slowing the progress of CHB-related diseases and providing psychological support early are the key points to improving the quality of life with the diseases. The utility values estimated in this study can provide a vital instrument for cost-effectiveness studies on CHB-related diseases.
